Juniper Pharmaceuticals (JNP) 10-Q 4 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 28, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	JNP
Entity Registrant Name	JUNIPER PHARMACEUTICALS INC
Entity Central Index Key	821,995
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		10,843,752

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 21,759	$ 20,994
Accounts receivable, net	4,505	6,573
Inventories	5,694	5,621
Prepaid expenses and other current assets	1,498	1,539
Total current assets	33,456	34,727
Property and equipment, net	13,834	13,366
Intangible assets, net	908	969
Goodwill	8,444	8,342
Other assets	167	167
Total assets	56,809	57,571
Liabilities, contingently redeemable preferred stock, and stockholders’ equity
Accounts payable	2,706	3,893
Accrued expenses and other	4,306	5,271
Deferred revenue	6,443	5,624
Current portion of long-term debt	508	204
Total current liabilities	13,963	14,992
Long-term debt, net of current portion	3,359	2,203
Other noncurrent liabilities	45	56
Total liabilities	17,367	17,251
Commitments and contingencies
Contingently redeemable series C preferred stock, 0.55 shares issued and outstanding (liquidation preference of $550)	550	550
Stockholders’ equity:
Preferred stock, $0.01 par value; 1,000 shares authorized Series B convertible preferred stock, 0.13 shares issued and outstanding (liquidation preference of $13)
Common stock $0.01 par value; 150,000 shares authorized; 12,257 issued and 10,844 outstanding at March 31, 2017 and December 31, 2016	123	123
Additional paid-in capital	290,971	290,636
Treasury stock (at cost), 1,413 shares at March 31, 2017 and December 31, 2016	(8,601)	(8,601)
Accumulated deficit	(238,801)	(237,360)
Accumulated other comprehensive loss	(4,800)	(5,028)
Total stockholders’ equity	38,892	39,770
Total liabilities, contingently redeemable preferred stock, and stockholders’ equity	$ 56,809	$ 57,571

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	12,257,000	12,257,000
Common stock, shares outstanding	10,844,000	10,844,000
Purchase of treasury shares	1,413,000	1,413,000
Series C Preferred Stock [Member]
Preferred stock, shares issued	550	550
Preferred stock, shares outstanding	550	550
Preferred stock, liquidation preference, value	$ 550	$ 550
Series B Convertible Preferred Stock [Member]
Preferred stock, shares issued	130	130
Preferred stock, shares outstanding	130	130
Preferred stock, liquidation preference, value	$ 13	$ 13

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues
Product revenues	$ 7,726,000	$ 6,325,000
Service revenues	3,521,000	3,253,000
Royalties		899,000
Total revenues	11,247,000	10,477,000
Cost of product revenues	4,313,000	4,027,000
Cost of service revenues	2,243,000	2,323,000
Total cost of revenues	6,556,000	6,350,000
Gross profit	4,691,000	4,127,000
Operating expenses
Sales and marketing	379,000	272,000
Research and development	1,346,000	2,133,000
General and administrative	4,421,000	3,460,000
Total operating expenses	6,146,000	5,865,000
Loss from operations	(1,455,000)	(1,738,000)
Interest expense, net	(28,000)	(26,000)
Other income, net	42,000	125,000
Total non-operating income	14,000	99,000
Loss before income taxes	(1,441,000)	(1,639,000)
Provision for income taxes	0	4,000
Net loss	$ (1,441,000)	$ (1,643,000)
Basic net loss per common share	$ (0.13)	$ (0.15)
Diluted net loss per common share	$ (0.13)	$ (0.15)
Basic weighted average common shares outstanding	10,803	10,789
Diluted weighted average common shares outstanding	10,803	10,789

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (1,441)	$ (1,643)
Other comprehensive income (loss) components:
Foreign currency translation	228	(664)
Total other comprehensive income (loss)	228	(664)
Comprehensive loss	$ (1,213)	$ (2,307)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities:
Net loss	$ (1,441)	$ (1,643)
Reconciliation of net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	484	489
Stock-based compensation expense	341	118
Changes in operating assets and liabilities:
Accounts receivable	2,107	(625)
Inventories	(72)	414
Prepaid expenses and other current assets	48	(406)
Other non-current assets		18
Accounts payable	(1,363)	1,927
Accrued expenses and other	(1,039)	(1,287)
Deferred rent	(9)	17
Deferred revenue	806	1,349
Net cash (used in) provided by operating activities	(138)	371
Investing activities:
Purchases of property and equipment	(520)	(720)
Net cash used in investing activities	(520)	(720)
Financing activities:
Proceeds from equipment loans	1,501
Principal payments on debt	(79)	(57)
Dividends paid	(7)	(7)
Net cash provided by (used in) financing activities	1,415	(64)
Effect of exchange rate changes on cash and cash equivalents	8	(18)
Net increase (decrease) in cash and cash equivalents	765	(431)
Cash and cash equivalents, beginning of period	20,994	13,901
Cash and cash equivalents, end of period	21,759	13,470
Supplemental cash flow information
Cash paid for interest	23	$ 22
Supplemental noncash investing
Purchases of equipment through accounts payable and accrued expenses	$ 215

Interim Condensed Consolidated

Interim Condensed Consolidated Financial Statements	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Interim Condensed Consolidated Financial Statements	(1) Interim Condensed Consolidated Financial Statements The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. It is recommended that these financial statements be read in conjunction with the consolidated financial statements and related notes that appear in the Annual Report on Form 10-K of Juniper Pharmaceuticals, Inc. (“Juniper” or the “Company”) for the year ended December 31, 2016 filed with the SEC on March 7, 2017 (the “2016 Annual Report”). In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2017, and its results of operations for the three months ended March 31, 2017 and 2016, and cash flows for the three months ended March 31, 2017 and 2016. The condensed consolidated balance sheet at December 31, 2016, was derived from audited annual financial statements, but does not contain all of the footnote disclosures from the annual financial statements. Results of operations for the three months ended March 31, 2017 are not necessarily indicative of the results for the year ending December 31, 2017 or any period thereafter. At March 31, 2017, cash and cash equivalents were $21.8 million. The Company’s future funding requirements depend on a number of factors, including the rate of market acceptance of its current and future products and services and the resources the Company devotes to developing and supporting the same. The Company believes that current cash and cash equivalents, as well as cash generated from operations, will be sufficient to meet anticipated cash needs for working capital, including advancing its product candidates, and capital expenditures through May 31, 2018. The Company may be dependent on its ability to raise additional capital to finance operations and fund research and development programs beyond May 31, 2018. If the Company is not able to raise additional capital on terms acceptable to it, or at all, as and when needed, it may be required to curtail its research and development programs. Management Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition, allowance for doubtful accounts, inventory reserve, impairment analysis of goodwill and intangibles including their useful lives, research and development accruals, deferred tax assets, liabilities and valuation allowances, and fair value of stock options. On an ongoing basis, management evaluates its estimates. Actual results could differ from those estimates.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventories	(2) Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Components of inventory cost include materials, labor and manufacturing overhead. Inventories consist of the following (in thousands): March 31, 2017 December 31, 2016 Raw materials $ 1,344 $ 856 Work in process 2,876 3,806 Finished goods 1,474 959 Total $ 5,694 $ 5,621

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	(3) Goodwill and Intangible Assets Changes to goodwill during the three months ended March 31, 2017 were as follows (in thousands): Total Balance—December 31, 2016 $ 8,342 Effects of foreign currency translation 102 Balance—March 31, 2017 $ 8,444 Intangible assets consist of the following at March 31, 2017 and December 31, 2016 (in thousands): Trademark Developed Technology Customer Relationships Total Gross carrying amount—March 31, 2017 $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (65 ) (284 ) (258 ) (607 ) Accumulated amortization (235 ) (663 ) (497 ) (1,395 ) Balance—March 31, 2017 $ — $ 423 $ 485 $ 908 Trademark Developed Technology Customer Relationships Total Gross carrying amount—December 31, 2016 $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (53 ) (298 ) (270 ) (621 ) Accumulated amortization (247 ) (617 ) (456 ) (1,320 ) Balance—December 31, 2016 $ — $ 455 $ 514 $ 969 Amortization expense related to developed technology is classified as a component of cost of service revenues in the accompanying consolidated statements of operations. Amortization expense related to trademark and customer relationships is classified as a component of general and administrative expenses in the accompanying consolidated statements of operations. Amortization expense for the three months ended March 31, 2017 and 2016 was $0.1 million. As of March 31, 2017, amortization expense on existing intangible assets for the next four years is as follows (in thousands): Year ending December 31, Total Remainder of 2017 $ 219 2018 268 2019 242 2020 179 Total $ 908

Debt and other Contractual Obli

Debt and other Contractual Obligations	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Debt and other Contractual Obligations	(4) Debt and other Contractual Obligations In September 2013, Juniper assumed debt of $3.9 million in connection with its acquisition of Juniper Pharma Services (“JPS”). JPS had entered into a Business Loan Agreement (“Loan Agreement”) covering three loan facilities with Lloyds TSB Bank (“Lloyds”) as administrative agent. JPS had drawn down $3.9 million and as of March 31, 2017 owed $2.4 million. The three loan facilities are each repayable by monthly installments. Repayment began on one facility in February 2013 and the remaining two commenced in October 2013. All facilities are due for repayment over 15 years from the date of drawdown. Two of the facilities bear interest at the Bank of England’s base rate plus 1.95% and 2.55%, respectively. The interest rate at March 31, 2017 for these two facilities was 2.45% and 3.05%, respectively. The third facility is a fixed rate agreement bearing interest at 3.52% per annum. The weighted average interest rate for the three loan facilities for the three months ended March 31, 2017 was 3.00%. The Loan Agreement is secured by the mortgaged property and an unlimited lien on other assets of JPS. The Loan Agreement contains financial covenants that limit the amount of indebtedness JPS may incur, requires JPS to maintain certain levels of net worth, and restricts JPS’s ability to materially alter the character of its business. As of March 31, 2017, the Company is in compliance with all of the covenants under the Loan Agreement. In September 2013, as part of the acquisition of JPS, Juniper assumed a $2.5 million obligation under a grant arrangement with the Regional Growth Fund on behalf of the Secretary of State for Business, Innovation, and Skills in the United Kingdom. JPS used this grant to fund the building of its second facility, which includes analytical labs, office space, and a manufacturing facility. As part of the arrangement, JPS is required to create and maintain certain full-time equivalent personnel levels through October 2017. As of March 31, 2017, the Company is in compliance with the covenants of the arrangement. Juniper leases the buildings portion of its U.S. corporate office under an operating lease and debt for the Nottingham, U.K. facility. Additionally, Juniper leases certain equipment under loan agreements with payments through March 2022. In October 2015, the Company entered into a lease agreement for its corporate office in Boston, Massachusetts. The initial term of the lease agreement is approximately 39 months, which includes a three-month free rent period. In January and March 2017, the Company entered into loans of $0.9 million and $0.6 million, respectively, for equipment in its Nottingham, U.K. facility. The interest rate for the two loans was 2.09% at March 31, 2017. The transactions were considered failed sales-leaseback arrangements as the amount of the loans are less than the carrying value of the equipment. The initial terms of the loans are 60 months. Commitments under Juniper’s debt and lease arrangements are as follows as of March 31, 2017 (in thousands): Operating Leases Debt Principal Payments Total Remainder of 2017 $ 328 $ 364 $ 692 2018 443 501 944 2019 74 520 594 2020 — 539 539 2021 — 557 557 Thereafter — 1,386 1,386 Total minimum debt and lease payments $ 845 $ 3,867 $ 4,712 The income from the Regional Growth Fund will be recognized on a decelerated basis through October 2017. As of March 31, 2017, the obligation is valued at $0.4 million and is recorded as deferred revenue on the consolidated balance sheets. Other income associated with the Regional Growth Fund obligation for the three months ended March 31, 2017 and 2016 was $0.2 million. The amount of other income on the obligation that will be recognized provided the Company remains in compliance with the covenants will be the following (in thousands): Total Remainder of 2017 $ 400 Total $ 400

Intravaginal Ring Technology Li

Intravaginal Ring Technology License	3 Months Ended
	Mar. 31, 2017
Licensing Activities [Abstract]
Intravaginal Ring Technology License	(5) Intravaginal Ring Technology License In March 2015, the Company obtained an exclusive worldwide license (“License Agreement”) to the intellectual property rights for a novel segmented intravaginal ring (“IVR”) technology. Due to its novel polymer and segmentation composition, the Company believes the IVR has the potential to deliver one or more drugs, including hormones and larger molecules such as peptides, at different dosages and release rates within a single segmented ring. Drugs such as progesterone and leuprolide have already been tested using the technology and demonstrated sustained release for up to three weeks. This technology was developed by Dr. Robert Langer from the Massachusetts Institute of Technology (“MIT”) and Dr. William Crowley from Massachusetts General Hospital (“MGH”) and Harvard Medical School. Drs. Langer and Crowley have each agreed to serve a three-year term as strategic advisors to the Company in exchange for an upfront one-time payment plus quarterly fees and equity compensation. Unless earlier terminated by the parties, the License Agreement will remain in effect until the later of (i) the date on which all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned and (ii) one year after the last sale for which a royalty is due under the License Agreement or 10 years after such expiration or abandonment date referred to in (i), whichever is earlier. Juniper has the right to terminate the License Agreement by giving 90 days advance written notice to MGH. MGH has the right to terminate the License Agreement based on the Company’s failure to make payments due under the License Agreement, subject to a 15 day cure period, or the Company’s failure to maintain the insurance required by the License Agreement. MGH may also terminate the License Agreement based on Juniper’s non-financial default under the License Agreement, subject to a 60 day cure period. Pursuant to the terms of the License Agreement, Juniper has agreed to reimburse MGH for all costs associated with the preparation, filing, prosecution and maintenance of the licensed patent rights, and has agreed to pay MGH a $50,000 annual license fee on each of the first five year anniversaries of the effective date of the License Agreement, and a $100,000 annual license fee beginning on the sixth anniversary of the effective date of the License Agreement and on each subsequent anniversary thereafter. The annual license fee is creditable against any royalties or sublicense income payable in each calendar year. Under the terms of the License Agreement, Juniper has agreed to use commercially reasonable efforts to develop and commercialize at least one product and/or process related to the IVR technology, which efforts will include the making of certain minimum annual expenditures in each of the first five years following the effective date of the License Agreement. Juniper has also agreed to pay MGH certain milestone payments totaling up to $1.2 million tied to the Company’s achievement of certain development and commercialization milestones, and certain annual royalty payments based on net sales of any such patented products or processes developed by Juniper.

Segments and Geographic Informa

Segments and Geographic Information	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Segments and Geographic Information	(6) Segments and Geographic Information The Company and its subsidiaries currently operate in two segments: product and service. The product segment oversees the supply chain and manufacturing of CRINONE, the Company’s sole commercialized product. The product segment included the royalty stream the Company received from Allergan for CRINONE sales in the United States, which ceased with the November 2016 agreement with Allergan, as well as the development of new product candidates. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services for the Company’s customers, as well as the characterizing and developing of pharmaceutical product candidates for the Company’s internal programs and managing certain preclinical activities including manufacturing of the Company’s pipeline products. In September 2013, the Company acquired JPS, a U.K.-based provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry. The Company has integrated its supply chain management for its sole commercialized product, CRINONE, into those operations and have therefore sought to capture synergies by transferring all operational activities related to its historic business. The Company owns certain plant and equipment physically located at third party contractor facilities in the United Kingdom and Switzerland. The Company conducts its advanced formulation, analytical and consulting services through its subsidiary, JPS. The Company’s largest customer, Merck KGaA, utilizes a Switzerland-based subsidiary to acquire product from the Company, which it then sells throughout the world excluding the United States. The Company’s primary domestic customer, Allergan, Plc (“Allergan”), is responsible for the commercialization and sale of CRINONE in the United States. In November 2016, the Company entered into an agreement with Allergan to monetize future royalty payments. Under the agreement, the Company received a one-time payment of $11.0 million representing all future royalty amounts payable. The following tables show selected information by geographic area (in thousands): Revenues: Three Months Ended March 31, 2017 2016 United States $ 1,628 $ 1,794 Switzerland 7,757 6,341 United Kingdom 949 1,351 Other countries 913 991 Total $ 11,247 $ 10,477 Total assets: March 31, 2017 December 31, 2016 United States $ 21,589 $ 21,423 Switzerland 2,319 4,673 United Kingdom 32,730 31,288 Other countries 171 187 Total $ 56,809 $ 57,571 Long-lived assets: March 31, 2017 December 31, 2016 United States $ 698 $ 663 Switzerland 225 369 United Kingdom 13,983 13,468 Other countries 3 2 Total $ 14,909 $ 14,502 No other individual country represented greater than 10% of total revenues, total assets, or total long-lived assets for any period presented. For the three months ended March 31, 2017, Merck KGaA accounted for 100% of the product segment revenue. For the three months ended March 31, 2016, Merck KGaA and Allergan accounted for 88% and 12% of the product segment revenue, respectively. For the three months ended March 31, 2017 one customer accounted for 17% of the service segment total revenue. No additional customers accounted for 10% or more of the service segment total revenue for the three months ended March 31, 2017. No customers accounted for 10% or more of the service segment total revenue for the three months ended March 31, 2016. For the three months ended March 31, 2017, two customers accounted for 14% and 11% of total service segment accounts receivable, respectively. No other customers accounted for greater than 10% of the service segment accounts receivable. At March 31, 2016, one customer accounted for 11% of total service segment net accounts receivable. The following summarizes other information by segment for the three months ended March 31, 2017 (in thousands): Product Service Total Revenues Product revenues $ 7,726 $ — $ 7,726 Service revenues — 3,521 3,521 Total revenues $ 7,726 $ 3,521 $ 11,247 Cost of product revenues $ 4,313 $ — $ 4,313 Cost of service revenues — 2,243 2,243 Total cost of revenues $ 4,313 $ 2,243 $ 6,556 Gross profit $ 3,413 $ 1,278 $ 4,691 Total operating expenses 6,146 Total non-operating income 14 Loss before income taxes $ (1,441 ) The following summarizes other information by segment for the three months ended March 31, 2016 (in thousands): Product Service Total Revenues Product revenues $ 6,325 $ — $ 6,325 Service revenues — 3,253 3,253 Royalties 899 — 899 Total revenues $ 7,224 $ 3,253 $ 10,477 Cost of product revenues $ 4,027 $ — $ 4,027 Cost of service revenues — 2,323 2,323 Total cost of revenues $ 4,027 $ 2,323 $ 6,350 Gross profit $ 3,197 $ 930 $ 4,127 Total operating expenses 5,865 Total non-operating income 99 Loss before income taxes $ (1,639 )

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment	(7) Property and Equipment Property and equipment consists of the following (in thousands): Estimated Useful Life (Years) March 31, 2017 December 31, 2016 Machinery and equipment 3-10 $ 9,563 $ 8,628 Furniture and fixtures 3-5 1,190 1,190 Computer equipment and software 3-5 541 538 Buildings Up to 39 7,399 7,310 Land Indefinite 475 469 Construction in-process 1,452 1,567 20,620 19,702 Less: Accumulated depreciation (6,786 ) (6,336 ) Total $ 13,834 $ 13,366 Depreciation expense was $0.4 million for the three month periods ended March 31, 2017 and 2016. Machinery and equipment includes $1.6 million of equipment purchased under equipment loans.

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Net Loss Per Common Share	(8) Net Loss Per Common Share The calculation of basic and diluted loss per common share and common share equivalents is as follows (in thousands except for per share data): Three Months Ended March 31, 2017 2016 Basic net loss per common share Net loss $ (1,441 ) $ (1,643 ) Less: Preferred stock dividends (7 ) (7 ) Net loss applicable to common stock $ (1,448 ) $ (1,650 ) Basic weighted average number of common shares outstanding 10,803 10,789 Basic net loss per common share $ (0.13 ) $ (0.15 ) Diluted loss per common share Net loss applicable to common stock $ (1,448 ) $ (1,650 ) Add: Preferred stock dividends 7 7 Net loss applicable to dilutive common stock $ (1,441 ) $ (1,643 ) Basic weighted average number of common shares outstanding 10,803 10,789 Effect of dilutive securities Diluted weighted average number of common shares outstanding 10,803 10,789 Diluted net loss per common share $ (0.13 ) $ (0.15 ) Basic net loss per common share is computed by dividing the net loss, less preferred dividends, by the weighted-average number of shares of common stock outstanding during a period. The diluted loss per common share calculation gives effect to dilutive options, convertible preferred stock, and other potential dilutive common stock including restricted shares of common stock outstanding during the period. Diluted net loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options, assuming the exercise of all in-the-money stock options. Common share equivalents have been excluded where their inclusion would be anti-dilutive. Shares to be issued upon the exercise of the outstanding options, convertible preferred stock, and selected restricted shares of common stock excluded from the income per share calculation amounted to 2.3 million and 1.4 million in the three month periods ended March 31, 2017 and 2016, respectively, because the awards were anti-dilutive as the Company was in a net loss position.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Accumulated Other Comprehensive Loss	(9) Accumulated Other Comprehensive Loss Changes to accumulated other comprehensive loss during the three months ended March 31, 2017 were as follows (in thousands): Translation Adjustment Balance—December 31, 2016 $ (5,028 ) Current period other comprehensive income (loss) 228 Balance—March 31, 2017 $ (4,800 )

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	(10) Stock-Based Compensation Stock-based compensation expense was $0.3 million and $0.1 million for the three months ended March 31, 2017 and 2016, respectively. Stock-based compensation relates to options granted to employees, non-employee members of the Board of Directors and non-employees, time-based restricted stock units granted to employees and non-employee members of the Board of Directors and performance-based restricted stock units granted to employees. Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individuals holding the respective awards as follows (in thousands): Three Months Ended March 31, 2017 2016 Cost of revenues $ 28 $ 26 Sales and marketing 11 14 Research and development (43 ) (146 ) General and administrative 345 224 Total $ 341 $ 118 There were no option exercises in the three months ended March 31, 2017 and 2016. Juniper granted options to purchase 655,400 shares of common stock to employees and non-employee directors in the three months ended March 31, 2017 and options to purchase 397,500 shares of common stock to employees during the three months ended March 31, 2016. Stock options granted to employees typically vest over a four-year term. Stock options granted to non-employee directors typically vest over a three-year term. Juniper granted 52,700 time-based restricted stock units to employees during the three months ended March 31, 2017. No time-based restricted stock units were granted during the three months ended March 31, 2016. Juniper granted 181,000 performance-based restricted stock units to employees during the three months ended March 31, 2017. No performance-based restricted stock units were granted during the three months ended March 31, 2016. The performance-based restricted stock units vest based on the occurrence of certain operational and strategic events which were determined by the Company’s Board of Directors. The Company uses the Black-Scholes option pricing model to determine the estimated grant date fair values for stock options and estimates the fair value of time-based restricted stock units and performance-based restricted stock units based on the closing price of the Company’s common stock on the date of grant. The Company’s assumptions do not include an estimated forfeiture rate. The weighted-average grant date fair values of options granted to employees during the three months ended March 31, 2017 and 2016 were $2.44 and $4.81, respectively, using the following assumptions: Three Months Ended March 31, 2017 2016 Risk free interest rate 1.45% - 1.48% 1.14% Expected term 4.5 - 4.75 years 4.75 years Dividend yield — — Expected volatility 54.6% - 55.2% 79.23% - 79.29% The Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options, which is re-measured over the graded vesting term resulting in periodic adjustments to stock-based compensation expense. The stock-based compensation expense recorded for non-employees is primarily reflected in the research and development line of the statement of operations and is remeasured on a quarterly basis from the date of grant. During the three months ended March 31, 2017 the Company recorded a reduction of stock-based compensation expense of $0.1 million for non-employee options as a result of changes in the fair value of the options during the period. During the three months ended March 31, 2016 the Company recorded a reduction of stock-based compensation expense of $0.2 million for non-employee options. No tax benefit has been recognized due to the net tax losses during the periods presented. There were no options granted to non-employees during the three months ended March 31, 2017 and 2016. Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. Juniper’s estimated expected stock price volatility is based on its own historical volatility. Juniper’s expected term of options granted during the three months ended March 31, 2017 and 2016 was derived using the simplified method for employees. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The weighted-average grant date fair value of both the time-based restricted stock units and performance-based restricted stock units was $5.15 during the three months ended March 31, 2017. The Company recognizes stock-based compensation expense for time-based restricted stock units over the vesting period. For performance-based restricted stock units, the Company considers the performance criteria at each balance sheet date and recognizes stock-based compensation expense for those criteria considered probable. The criteria associated with these performance-based stock units were not determined to be probable at March 31, 2017 and as such, no expense was recorded. As of March 31, 2017, the total unrecognized compensation cost related to outstanding stock options, time-based restricted stock units and performance-based restricted stock units expected to vest was $5.7 million, which the Company expects to recognize over a weighted-average period of 3.19 years.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(11) Fair Value of Financial Instruments U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the amount that would be received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: Level 1: Quoted prices in active markets for identical assets and liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value of cash and cash equivalents are classified as Level 1 at March 31, 2017 and December 31, 2016. The fair values of accounts receivable and accounts payable approximate their respective carrying amounts. The Company’s long-term debt is carried at amortized face value, which approximates fair value based on current market pricing of similar debt instruments and is categorized as a Level 2 measurement.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	(12) Income Taxes During the three months ended March 31, 2017 Juniper recorded no income tax expense due to expected losses forecasted for the year. During the three months ended March 31, 2016, Juniper recorded income tax expense of $4,000, representing an effective tax rate of (0.2)%. The income tax provision for the three months ended March 31, 2016, is primarily attributable to state minimum taxes owed. Juniper files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. Juniper is no longer subject to U.S. federal income tax examinations by tax authorities for years prior to 2012. Additionally, with few exceptions, Juniper is no longer subject to U.S. state tax examinations for years prior to 2012.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2017
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Pronouncements	(13) Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Recognition and Measurement of Financial Assets and Financial Liabilities In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition Revenue Recognition-Construction-Type and Production-Type Contracts In February 2016, the FASB issued ASU No. 2016-02, Leases In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment

Interim Condensed Consolidate20

Interim Condensed Consolidated Financial Statements (Policies)	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Management Estimates	Management Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition, allowance for doubtful accounts, inventory reserve, impairment analysis of goodwill and intangibles including their useful lives, research and development accruals, deferred tax assets, liabilities and valuation allowances, and fair value of stock options. On an ongoing basis, management evaluates its estimates. Actual results could differ from those estimates.
Recent Accounting Pronouncements	In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Recognition and Measurement of Financial Assets and Financial Liabilities In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition Revenue Recognition-Construction-Type and Production-Type Contracts In February 2016, the FASB issued ASU No. 2016-02, Leases In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following (in thousands): March 31, 2017 December 31, 2016 Raw materials $ 1,344 $ 856 Work in process 2,876 3,806 Finished goods 1,474 959 Total $ 5,694 $ 5,621

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Changes to Goodwill	Changes to goodwill during the three months ended March 31, 2017 were as follows (in thousands): Total Balance—December 31, 2016 $ 8,342 Effects of foreign currency translation 102 Balance—March 31, 2017 $ 8,444
Changes to Intangible Assets	Intangible assets consist of the following at March 31, 2017 and December 31, 2016 (in thousands): Trademark Developed Technology Customer Relationships Total Gross carrying amount—March 31, 2017 $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (65 ) (284 ) (258 ) (607 ) Accumulated amortization (235 ) (663 ) (497 ) (1,395 ) Balance—March 31, 2017 $ — $ 423 $ 485 $ 908 Trademark Developed Technology Customer Relationships Total Gross carrying amount—December 31, 2016 $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (53 ) (298 ) (270 ) (621 ) Accumulated amortization (247 ) (617 ) (456 ) (1,320 ) Balance—December 31, 2016 $ — $ 455 $ 514 $ 969
Amortization Expense on Existing Intangible Assets for Next Four Years	As of March 31, 2017, amortization expense on existing intangible assets for the next four years is as follows (in thousands): Year ending December 31, Total Remainder of 2017 $ 219 2018 268 2019 242 2020 179 Total $ 908

Debt and other Contractual Ob23

Debt and other Contractual Obligations (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Schedule of Commitments Under Juniper's Debt and Lease Arrangements	Commitments under Juniper’s debt and lease arrangements are as follows as of March 31, 2017 (in thousands): Operating Leases Debt Principal Payments Total Remainder of 2017 $ 328 $ 364 $ 692 2018 443 501 944 2019 74 520 594 2020 — 539 539 2021 — 557 557 Thereafter — 1,386 1,386 Total minimum debt and lease payments $ 845 $ 3,867 $ 4,712
Summary of Other Income on Obligation	The amount of other income on the obligation that will be recognized provided the Company remains in compliance with the covenants will be the following (in thousands): Total Remainder of 2017 $ 400 Total $ 400

Segments and Geographic Infor24

Segments and Geographic Information (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Selected Information by Geographic Area	The following tables show selected information by geographic area (in thousands): Revenues: Three Months Ended March 31, 2017 2016 United States $ 1,628 $ 1,794 Switzerland 7,757 6,341 United Kingdom 949 1,351 Other countries 913 991 Total $ 11,247 $ 10,477 Total assets: March 31, 2017 December 31, 2016 United States $ 21,589 $ 21,423 Switzerland 2,319 4,673 United Kingdom 32,730 31,288 Other countries 171 187 Total $ 56,809 $ 57,571 Long-lived assets: March 31, 2017 December 31, 2016 United States $ 698 $ 663 Switzerland 225 369 United Kingdom 13,983 13,468 Other countries 3 2 Total $ 14,909 $ 14,502
Schedule of Other Information by Segment	The following summarizes other information by segment for the three months ended March 31, 2017 (in thousands): Product Service Total Revenues Product revenues $ 7,726 $ — $ 7,726 Service revenues — 3,521 3,521 Total revenues $ 7,726 $ 3,521 $ 11,247 Cost of product revenues $ 4,313 $ — $ 4,313 Cost of service revenues — 2,243 2,243 Total cost of revenues $ 4,313 $ 2,243 $ 6,556 Gross profit $ 3,413 $ 1,278 $ 4,691 Total operating expenses 6,146 Total non-operating income 14 Loss before income taxes $ (1,441 ) The following summarizes other information by segment for the three months ended March 31, 2016 (in thousands): Product Service Total Revenues Product revenues $ 6,325 $ — $ 6,325 Service revenues — 3,253 3,253 Royalties 899 — 899 Total revenues $ 7,224 $ 3,253 $ 10,477 Cost of product revenues $ 4,027 $ — $ 4,027 Cost of service revenues — 2,323 2,323 Total cost of revenues $ 4,027 $ 2,323 $ 6,350 Gross profit $ 3,197 $ 930 $ 4,127 Total operating expenses 5,865 Total non-operating income 99 Loss before income taxes $ (1,639 )

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following (in thousands): Estimated Useful Life (Years) March 31, 2017 December 31, 2016 Machinery and equipment 3-10 $ 9,563 $ 8,628 Furniture and fixtures 3-5 1,190 1,190 Computer equipment and software 3-5 541 538 Buildings Up to 39 7,399 7,310 Land Indefinite 475 469 Construction in-process 1,452 1,567 20,620 19,702 Less: Accumulated depreciation (6,786 ) (6,336 ) Total $ 13,834 $ 13,366

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Calculation of Basic and Diluted Loss Per Common Share and Common Share Equivalents	The calculation of basic and diluted loss per common share and common share equivalents is as follows (in thousands except for per share data): Three Months Ended March 31, 2017 2016 Basic net loss per common share Net loss $ (1,441 ) $ (1,643 ) Less: Preferred stock dividends (7 ) (7 ) Net loss applicable to common stock $ (1,448 ) $ (1,650 ) Basic weighted average number of common shares outstanding 10,803 10,789 Basic net loss per common share $ (0.13 ) $ (0.15 ) Diluted loss per common share Net loss applicable to common stock $ (1,448 ) $ (1,650 ) Add: Preferred stock dividends 7 7 Net loss applicable to dilutive common stock $ (1,441 ) $ (1,643 ) Basic weighted average number of common shares outstanding 10,803 10,789 Effect of dilutive securities Diluted weighted average number of common shares outstanding 10,803 10,789 Diluted net loss per common share $ (0.13 ) $ (0.15 )

Accumulated Other Comprehensi27

Accumulated Other Comprehensive Loss (Tables)	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Loss	Changes to accumulated other comprehensive loss during the three months ended March 31, 2017 were as follows (in thousands): Translation Adjustment Balance—December 31, 2016 $ (5,028 ) Current period other comprehensive income (loss) 228 Balance—March 31, 2017 $ (4,800 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2017
Schedule of Stock-Based Compensation Expense Allocation	Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individuals holding the respective awards as follows (in thousands): Three Months Ended March 31, 2017 2016 Cost of revenues $ 28 $ 26 Sales and marketing 11 14 Research and development (43 ) (146 ) General and administrative 345 224 Total $ 341 $ 118
Employees [Member]
Assumptions Used to Value Options Granted	The weighted-average grant date fair values of options granted to employees during the three months ended March 31, 2017 and 2016 were $2.44 and $4.81, respectively, using the following assumptions Three Months Ended March 31, 2017 2016 Risk free interest rate 1.45% - 1.48% 1.14% Expected term 4.5 - 4.75 years 4.75 years Dividend yield — — Expected volatility 54.6% - 55.2% 79.23% - 79.29%

Interim Condensed Consolidate29

Interim Condensed Consolidated Financial Statements - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Cash and cash equivalents	$ 21,759	$ 20,994	$ 13,470	$ 13,901

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory Net Items Net Of Reserve Alternative [Abstract]
Raw materials	$ 1,344	$ 856
Work in process	2,876	3,806
Finished goods	1,474	959
Total	$ 5,694	$ 5,621

Goodwill and Intangible Asset31

Goodwill and Intangible Assets - Schedule of Changes to Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning balance	$ 8,342
Effects of foreign currency translation	102
Ending balance	$ 8,444

Goodwill and Intangible Asset32

Goodwill and Intangible Assets - Changes to Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,910	$ 2,910
Foreign currency translation adjustment	(607)	(621)
Accumulated amortization	(1,395)	(1,320)
Balance	908	969
Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	300	300
Foreign currency translation adjustment	(65)	(53)
Accumulated amortization	(235)	(247)
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,370	1,370
Foreign currency translation adjustment	(284)	(298)
Accumulated amortization	(663)	(617)
Balance	423	455
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,240	1,240
Foreign currency translation adjustment	(258)	(270)
Accumulated amortization	(497)	(456)
Balance	$ 485	$ 514

Goodwill and Intangible Asset33

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Intangible Liability Disclosure [Abstract]
Amortization expense	$ 0.1	$ 0.1

Goodwill and Intangible Asset34

Goodwill and Intangible Assets - Amortization Expense on Existing Intangible Assets for Next Four Years (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
Remainder of 2017	$ 219
2,018	268
2,019	242
2,020	179
Total	$ 908	$ 969

Debt and Other Contractual Ob35

Debt and Other Contractual Obligations - Additional Information (Detail) $ in Thousands	1 Months Ended			3 Months Ended
	Mar. 31, 2017USD ($)	Jan. 31, 2017USD ($)	Sep. 30, 2013USD ($)	Mar. 31, 2017USD ($)FacilityLoan	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)
Debt Instrument [Line Items]
Owes due to foreign currency revaluation	$ 3,867			$ 3,867
Lease agreement term				39 months
Lease agreement rent free period				3 months
Capital lease term				60 months
Proceeds from equipment loans				$ 1,501
Deferred revenue	$ 6,443			$ 6,443		$ 5,624
Loan for Equipment [Member] | Nottingham, UK Facility [Member]
Debt Instrument [Line Items]
Number of loans | Loan				2
Loan for Equipment [Member] | Loan One [Member] | Nottingham, UK Facility [Member]
Debt Instrument [Line Items]
Interest rate at the end of period	2.09%			2.09%
Proceeds from equipment loans		$ 900
Loan for Equipment [Member] | Loan Two [Member] | Nottingham, UK Facility [Member]
Debt Instrument [Line Items]
Interest rate at the end of period	2.09%			2.09%
Proceeds from equipment loans	$ 600
Juniper Pharma Services [Member]
Debt Instrument [Line Items]
Debt assumed			$ 3,900
Number of loan facilities | Facility				3
Withdrawn amount				$ 3,900
Owes due to foreign currency revaluation	$ 2,400			$ 2,400
Loan facilities repayment period				15 years
Weighted average interest rate for the period	3.00%			3.00%
Business acquisition maturity period				2017-10
Juniper Pharma Services [Member] | Regional Growth Fund [Member]
Debt Instrument [Line Items]
Debt assumed			$ 2,500
Other income				$ 200	$ 200
Deferred revenue	$ 400			$ 400
Juniper Pharma Services [Member] | Loan Facility One [Member]
Debt Instrument [Line Items]
Loan repayment commencement period				2013-02
Loan facilities bear interest rate				1.95%
Loan facility interest rate description				base rate plus 1.95%
Interest rate at the end of period	2.45%			2.45%
Juniper Pharma Services [Member] | Loan Facility Two [Member]
Debt Instrument [Line Items]
Loan repayment commencement period				2013-10
Loan facilities bear interest rate				2.55%
Loan facility interest rate description				base rate plus 2.55%
Interest rate at the end of period	3.05%			3.05%
Juniper Pharma Services [Member] | Loan Facility Three [Member]
Debt Instrument [Line Items]
Loan repayment commencement period				2013-10
Loan facilities bear interest rate	3.52%			3.52%

Debt and Other Contractual Ob36

Debt and Other Contractual Obligations - Schedule of Commitments Under Juniper's Debt and Lease Arrangements (Detail) $ in Thousands	Mar. 31, 2017USD ($)
Debt Disclosure [Abstract]
Operating Leases, Remainder of 2017	$ 328
Operating Leases, 2018	443
Operating Leases, 2019	74
Operating Leases, Total minimum lease payments	845
Debt Principal Payments, Remainder of 2017	364
Debt Principal Payments, 2018	501
Debt Principal Payments, 2019	520
Debt Principal Payments, 2020	539
Debt Principal Payments, 2021	557
Debt Principal Payments, Thereafter	1,386
Total Debt Principal Payments, minimum	3,867
Total Debt and Lease payments, Remainder of 2017	692
Total Debt and Lease payments, 2018	944
Total Debt and Lease payments, 2019	594
Total Debt and Lease payments, 2020	539
Total Debt and Lease payments, 2021	557
Total Debt and Lease payments, Thereafter	1,386
Total minimum debt and lease payments	$ 4,712

Debt and Other Contractual Ob37

Debt and Other Contractual Obligations - Summary of Other Income on Obligation (Detail) $ in Thousands	Mar. 31, 2017USD ($)
Contractual Obligation [Line Items]
Remainder of 2017	$ 692
Total minimum debt and lease payments	4,712
Regional Growth Fund [Member] | Juniper Pharma Services [Member]
Contractual Obligation [Line Items]
Remainder of 2017	400
Total minimum debt and lease payments	$ 400

Intravaginal Ring Technology 38

Intravaginal Ring Technology License - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017USD ($)
License Agreements [Line Items]
License agreement notice period	90 days
License fee payment	$ 50,000
License fee payment beginning on the sixth anniversary	100,000
Milestone payment	$ 1,200,000
Financial Default [Member]
License Agreements [Line Items]
Cure period	15 days
Non Financial Default [Member]
License Agreements [Line Items]
Cure period	60 days

Segments and Geographic Infor39

Segments and Geographic Information - Additional Information (Detail) $ in Thousands	1 Months Ended	3 Months Ended
	Nov. 30, 2016USD ($)	Mar. 31, 2017SegmentCustomer	Mar. 31, 2016USD ($)Customer
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segments | Segment		2
One time payment, royalty revenues | $			$ 899
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Product Segment [Member] | Customer One [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage		17.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Service [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Customers accounted for 10% or more of total revenues | Customer		1	0
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Product Segment [Member] | Customer Two [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage		11.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Service [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of customers | Customer		2	1
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Service [Member] | Customer One [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage		14.00%	11.00%
Allergan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
One time payment, royalty revenues | $	$ 11,000
Allergan [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Product Segment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage			12.00%
Merck KGaA [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Product Segment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage		100.00%	88.00%

Segments and Geographic Infor40

Segments and Geographic Information - Selected Information by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 11,247	$ 10,477
Total assets	56,809		$ 57,571
Total Long-lived assets	14,909		14,502
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	1,628	1,794
Total assets	21,589		21,423
Total Long-lived assets	698		663
Switzerland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	7,757	6,341
Total assets	2,319		4,673
Total Long-lived assets	225		369
Nottingham, UK Facility [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	949	1,351
Total assets	32,730		31,288
Total Long-lived assets	13,983		13,468
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	913	$ 991
Total assets	171		187
Total Long-lived assets	$ 3		$ 2

Segments and Geographic Infor41

Segments and Geographic Information - Schedule of Other Information by Segment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues
Product revenues	$ 7,726	$ 6,325
Service revenues	3,521	3,253
Royalties		899
Total revenues	11,247	10,477
Cost of product revenues	4,313	4,027
Cost of service revenues	2,243	2,323
Total cost of revenues	6,556	6,350
Gross profit	4,691	4,127
Total operating expenses	6,146	5,865
Total non-operating income	14	99
Loss before income taxes	(1,441)	(1,639)
Product [Member]
Revenues
Product revenues	7,726	6,325
Royalties		899
Total revenues	7,726	7,224
Cost of product revenues	4,313	4,027
Total cost of revenues	4,313	4,027
Gross profit	3,413	3,197
Service [Member]
Revenues
Service revenues	3,521	3,253
Total revenues	3,521	3,253
Cost of service revenues	2,243	2,323
Total cost of revenues	2,243	2,323
Gross profit	$ 1,278	$ 930

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 20,620	$ 19,702
Less: Accumulated depreciation	(6,786)	(6,336)
Total	13,834	13,366
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 9,563	8,628
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	10 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 1,190	1,190
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	5 years
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 541	538
Computer Equipment and Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Computer Equipment and Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	5 years
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 7,399	7,310
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	39 years
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 475	469
Property, plant and equipment useful life (in years)	Indefinite
Construction in-Process [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 1,452	$ 1,567

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Depreciation [Abstract]
Depreciation expense	$ 0.4	$ 0.4
Equipment purchased under equipment loans	$ 1.6

Net Loss Per Common Share - Cal

Net Loss Per Common Share - Calculation of Basic and Diluted Loss Per Common Share and Common Share Equivalents (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Basic net loss per common share
Net loss	$ (1,441)	$ (1,643)
Less: Preferred stock dividends	(7)	(7)
Net loss applicable to common stock	$ (1,448)	$ (1,650)
Basic weighted average number of common shares outstanding	10,803	10,789
Basic net loss per common share	$ (0.13)	$ (0.15)
Diluted loss per common share
Net loss applicable to common stock	$ (1,448)	$ (1,650)
Add: Preferred stock dividends	7	7
Net loss applicable to dilutive common stock	$ (1,441)	$ (1,643)
Basic weighted average number of common shares outstanding	10,803	10,789
Diluted weighted average number of common shares outstanding	10,803	10,789
Diluted net loss per common share	$ (0.13)	$ (0.15)

Net Loss Per Common Share - Add

Net Loss Per Common Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	2.3	1.4

Accumulated Other Comprehensi46

Accumulated Other Comprehensive Loss - Schedule of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance—December 31, 2016	$ 39,770
Current period other comprehensive income (loss)	228	$ (664)
Balance—March 31, 2017	38,892
Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance—December 31, 2016	(5,028)
Current period other comprehensive income (loss)	228
Balance—March 31, 2017	$ (4,800)

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 300,000	$ 100,000
Stock option exercised	0	0
Tax benefit recognized	$ 0	$ 0
Stock-based compensation expense	341,000	$ 118,000
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized	$ 5,700,000
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition	3 years 2 months 9 days
Time-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair values of options granted	$ 5.15
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair values of options granted	$ 5.15
Stock-based compensation expense	$ 0
Employees and Non-Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted	655,400
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		397,500
Share-based compensation arrangement by share-based payment award, award vesting period	4 years
Weighted-average grant date fair values of options granted	$ 2.44	$ 4.81
Employees [Member] | Time-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-options stock granted	52,700	0
Employees [Member] | Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-options stock granted	181,000	0
Non-Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period	3 years
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted	0	0
Stock-based compensation expense	$ 100,000	$ 200,000

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Allocation (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	$ 341	$ 118
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	28	26
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	11	14
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	(43)	(146)
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	$ 345	$ 224

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions Used to Value Options Granted (Detail) - Employees [Member]	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.14%
Expected term		4 years 9 months
Dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.45%
Expected term	4 years 6 months
Expected volatility	54.60%	79.23%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.48%
Expected term	4 years 9 months
Expected volatility	55.20%	79.29%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 4,000
Effective tax rate		(0.20%)